-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For medical professionals only
At 19:00 on November 22, we invite you to study the heavy research style and enjoy the clinical benefits
of CHB treatment with you.
One of the international conferences in the field of hepatology every year is the annual meeting of the American Association for the Study of Liver Diseases (AASLD), where scholars present new research results to the world, so that the sharing and discussion with each other collide with more "sparks"
.
In the field of chronic hepatitis B (CHB), a variety of new hepatitis B drugs have made breakthroughs in clinical trials, and cutting-edge research progress in the clinical benefit data of long-term antiviral therapy and the selection of treatment regimens for various groups of CHB have brought new trends
of thought to the diagnosis, treatment and development of CHB.
Chinese scholars have also brought a number of research results, among which in terms of measures to interrupt mother-to-child transmission of HBV, Chinese scholars have shown through real-world research data [1] that in addition to vaccination and hepatitis B immunoglobulin (HBIG), antiviral treatment and preventive measures can greatly reduce transmission, making the mother-to-child transmission rate much lower than the WHO goal of eliminating mother-to-child transmission.
This may hopefully push the World Health Organization to rewrite its target of eliminating mother-to-child transmission of hepatitis B by 2030 [1].
There are also multiple real-world studies that add more evidence-based evidence for Chinese groups of CHB treatment
.
The 2022 AASLD Conference is all-encompassing, and the "China Hepatitis Cloud Forum: 2022 AASLD Hepatitis B Research Progress Express" will focus on your performance
.
At 19:00 on November 22, we invite you to study the heavy research style and enjoy the clinical benefits
of CHB treatment with you.
Professor Xie Wen of Beijing Ditan Hospital affiliated to Capital Medical University and Associate Professor Chen Enqiang of West China Hospital of Sichuan University were specially invited to be guests in the live broadcast room, selecting major research in the field of hepatitis B from the perspective of front-line participants, and combining it with clinical practice for wonderful interpretation and summary
.
< wonderful > on the "yards"
Professor Xie Wen
Beijing Ditan Hospital affiliated to Capital Medical University
Global epidemiological data on chronic HBV infection [2] show that most new chronic HBV infections globally occurred in children and adolescents in 2022, and while HBV vaccination campaigns have helped reduce HBV infection rates in children, all countries have been slow to achieve other HBV elimination targets [3].
How to implement personalized treatment plans for all types of CHB patients is still the focus of
clinical research.
The latest data from this AASLD conference show that strengthening patients' awareness of diseases and establishing a systematic reminder mechanism can reduce the loss rate of patients [4]; Tenofovir propofovir fumarate (TAF) can effectively inhibit HBV virus replication in various special populations, including children and adolescents [5], patients in the "uncertain stage" [6], patients with recurrent CHB after discontinuation [7] and patients with hepatitis B decompensated cirrhosis [8], with high drug resistance barrier and good safety
.
There are also studies [9] that TAF prophylaxis is effective in preventing HBV reactivation
in patients receiving antitumor or immunosuppressive therapy.
Proven – revisiting the clinical benefits of long-term antiviral therapy for CHB
Associate Professor Chen Enqiang
West China Hospital, Sichuan University
Previous data suggest that nearly 40% of chronic HBV infections are in an "uncertain period"
[10].
Patients in the uncertain phase have a significantly higher
risk of HCC (hepatocellular carcinoma) than those in the inactive phase.
The latest data from this AASLD show that HBV DNA > 1000 IU/mL and antiviral therapy in patients with uncertain CHB aged > 45 years can significantly reduce the risk of HCC [11]; In patients with compensated cirrhosis, the risk of HCC in untreated patients with hypoviremia (LLV) is significantly higher than in patients with undetectable HBV DNA levels [12], suggesting that patients with compensated cirrhosis with LLV should receive antiviral therapy, demonstrating the importance of
expanding HBV antiviral therapy.
Data on the clinical benefits of long-term treatment of CHB [13] show that long-term treatment with TAF may significantly reduce the degree of liver fibrosis and the incidence of liver-related adverse outcomes may also decrease, and the accumulation of real-world data also shows a good safety profile of long-term treatment with TAF [14-15].
。
More wonderful content locked in the live broadcast room, face to face with big coffee, share academic feast! See you on November 22 at 7 p.
m.
!
References[1] Yin, et al.
AASLD 2022.
Poster #1204.
[2] Razavi-Shearer, et al.
AASLD 2022.
Oral #30.
[3] Blach, et al.
AASLD 2022.
Oral #45.
[4] Lung, et al.
AASLD 2022.
Abstract #3550.
[5] Schwarz, et al.
AASLD 2022.
Poster #1184.
[6] Peng, et al.
AASLD 2022.
Poster #1106.
[7] Su, et al.
AASLD 2022.
Poster #1214.
[8] Guo ,et al.
AASLD 2022.
Poster #1143.
[9] Suda, et al.
AASLD 2022.
Poster #1172.
[10] Huang , et al.
Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase.
Clin Gastroenterol Hepatol, 2021.
[11] Huang et al.
AASLD 2022.
Oral #36.
[12] Yang et al.
AASLD 2022.
Oral #24.
[13] Huynh et al.
AASLD 2022.
Poster #1156.
[14] Bekta et al.
AASLD 2022.
Poster #1182.
[15] Ogawa et al.
AASLD 2022.
Poster #1160.
This information is for medical and scientific reference only and is not recommended for use in any manner inconsistent with the prescribed information approved in your country.
